FDA cardio panel backs approval of Medicines' cangrelor
This article was originally published in Scrip
Executive Summary
After a day of what often was intense debate, The Medicines Company (MDCO) managed to walk away with a solid majority of FDA panelists backing the firm's experimental drug cangrelor – something earlier at the meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) appeared to be a near impossibility to achieve.